000			05184nam a22004095i 4500
001			86570
003			ES-MaUEC
005			20230207040605.0
007			cr nn 008mamaa
008			150928s2016 ja | s |||| 0|eng d
020			_a9784431555827
040			_aES-MaUEC
050		4	_aRC776.F5 _b2016 EB
082	0	4	_a616.2
245	0	0	_aIdiopathic pulmonary fibrosis : _badvances in diagnostic tools and disease management _cedited by Hiroyuki Nakamura, Kazutetsu Aoshiba
250			_a1st ed
260			_aTokyo _bSpringer _c2016
300			_a1 recurso en línea (X, 259 p.) _b96 ilustraciones, 30 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart 1 -- Definition, epidemiology, and pathogenesis -- Chapter 1: Definition of IPF (Question: Is the latest classification [ATS/ERS] satisfactory?) -- Chapter 2: Epidemiology and risk factors of IPF (Question: Can we dare to ask, 2What are the possible causes?3) -- Chapter 3: Acute exacerbation of IPF (Question: The concept was proposed in Japan, but why was it not recognized in western countries?) -- Chapter 4: Pathogenesis (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?) -- Part 2 Diagnosis -- Chapter 5: Specific serum markers of IPF (Question: What are the significances of KL-6, SP-A, and SP-D?) -- Chapter 6: High-resolution CT of honeycombing and IPF/UIP (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?) -- Chapter 7: Pathology of IPF (Question: Why does the pathological classification of IIPs vary among pathologists?) -- Chapter 8: Differential diagnosis (Question: What should we particularly keep in mind in the differential diagnosis?) -- Part 3 Management and prognosis -- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds) (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?) -- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants) (Question: Are these actually effective? Ineffective? Harmful?) -- Chapter 11: Non-pharmacological therapy for IPF (Question: Is respiratory care actually effective?) -- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B) (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?) -- Part 4 Topics -- Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE) (Question: Is it an independent disease entity?) -- Chapter 14: Common pathways in IPF and lung cancer (Question: Why is lung cancer associated with IPF at a high frequency?) -- Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer (Question: Can acute exacerbation of IPF be predicted preoperatively?)
520			_aFrom epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cance
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650	0	4	_aFibrosis pulmonar _9469329
650		7	_aAparato respiratorio _xEnfermedades _0comprobar BNE19901053942 _2embne _9405936
650		7	_aCitoquinas _0comprobar BNE19930065472 _2embne _9147650
700	1		_aNakamura, Hiroyuki _eeditor literario _9100388 _0Local
700	1		_aAoshiba, Kazutetsu _eeditor literario _9100389 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-55582-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9784431555827
907			_a.b12958487 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b08-06-17 _cm _dz _eb _feng _gja _h0
945			_aRC776 .F5 I35 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1160007x _z06-04-17
999			_c86570 _d86570 _x1